Angiotensin Therapeutics is addressing renal RAS imbalance — a key driver of progressive kidney injury that is insufficiently corrected by current therapies. Unlike existing drugs that block angiotensin signaling indirectly, our recombinant ACE2 variant directly degrades excess angiotensin II—the hormone that drives inflammation, fibrosis, and blood vessel constriction in kidney disease. We’ve modified the protein to extend its half-life and improve targeting to the kidney, enabling sustained reduction of harmful RAAS activity and activation of protective counter-regulatory pathways. This approach addresses the limitations of standard RAS acting-agents, offering a more targeted and durable therapeutic strategy for preserving kidney function.

In addition, grant supported research  has shown  exceptionally promising results  of one of our soluble  ACE2  proteins to prevent SARS-CoV-2 infection targeting the ACE2 receptor  to intercept viral entry as a way to prevent COVID 10.